XXEC Inc. Makes New Investment in Abbott Laboratories $ABT

XXEC Inc. acquired a new stake in Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,049 shares of the healthcare product maker’s stock, valued at approximately $1,259,000. Abbott Laboratories comprises 1.2% of XXEC Inc.’s holdings, making the stock its 20th largest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth $26,000. Abound Financial LLC bought a new position in Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $27,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ABT. Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Mizuho lowered their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Barclays reduced their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Finally, Sanford C. Bernstein decreased their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories Trading Up 0.1%

Shares of ABT opened at $88.48 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The business has a 50-day moving average of $90.08 and a 200 day moving average of $106.60. The firm has a market cap of $154.12 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.